- Home
- ANY vs JSPR Comparison
ANY vs JSPR Comparison
Compare ANY & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | JSPR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 14.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANY | JSPR |
|---|---|---|
| Price | $1.60 | $0.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $30.00 | $15.50 |
| AVG Volume (30 Days) | 333.2K | ★ 732.4K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | N/A |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.32 |
| 52 Week High | $6.20 | $3.31 |
Technical Indicators
Market Signals| Indicator | ANY | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 64.82 |
| Support Level | $1.60 | $0.79 |
| Resistance Level | $1.80 | $1.06 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 2.89 | 65.60 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.